The SGLT2i group generally had a fewer history of comorbidities (e.g., coronary artery disease) and medication use (e.g., calcium channel blockers), despite having a higher proportion of use of HF medications at discharge such as, RASi, mineralocorticoid receptor antagonist, and angiotensin receptor/neprilysin inhibitor. The gene discussed is MME; the disease is coronary artery disorder.